Implementation of Revised ECDL-2025 in Pharmacy Module: ECHS Order dated 23.03.2026
Tele: 25683476
Central Organisation ECHS
ECHS Bhawan
Thimayya Marg
Near Gopinath Circle
Delhi Cantt-110010
B/49769/AG/ECHS dated 23 Mar 2026
IHQ of MoD (Navy)/Dir ECHS (N)
Air HQ (DAV)/Coord
HQ Southern Command (A/ECHS)
HQ Eastern Command (A/ECHS)
HQ Western Command (A/ECHS)
HQ Central Command (A/ECHS)
HQ Northern Command (A/ECHS)
HQ South Western Command (A/ECHS)
HQ Andaman & Nicobar Command (A/ECHS)
AMA ECHS, Embassy of India, Nepal
All Regional Centres
IMPLEMENTATION OF REVISED ECDL-2025 IN PHARMACY MODULE
1. Please refer the following:-
1.1. CO ECHS letter No B/49769/AG/ECHS dated 31 Jul 2024 on subject “Implementation Directives of ECHS CDL (ECDL-2024)”.
1.2. CO ECHS letter No B/49769/AG/ECHS dated 10 Nov 2025 on subject “Addendum to Implementation Directives of ECHS CDL (ECDL-2024).
2. The earlier ECDL-2024 was found to contain numerous duplicate entries, incorrect nomenclature, and primarily brand-name medicines instead of generic names. To standardize medicine nomenclature, remove duplication, and include SEMO-recommended medicines, ECDL-2024 has been revised. The revised ECDL-2025 has now been implemented in the pharmacy module and is also accessible in the doctors’ module at all ECHS Polyclinics.
3. Key Updates in the Medicine List:-
2.1. Incorporation of medicines recommended by the respective SEMOs, including anti-cancer and essential medicines.
2.2. Inclusion of only generic names with correct dose, dosages forms and all brand names have been eliminated.
2.3. Inactivation of duplicate entries.
4. The revised ECDL-2025 comprises a total of 2446 medicines and consumables, updated in accordance with current requirements (Appendix ‘A’). A total of 473 medicines and consumables have been newly incorporated into ECDL-2025.
5. Further, 166 medicines and consumables listed in ECDL-2024 have been declared inactive (Appendix ‘B’) for the following reasons: duplicate nomenclature, incorrect nomenclature, classification as nutraceuticals/cosmetics and combinations banned by Central Drug Standard Control Organization (CDSCO). It is requested that necessary stock adjustments be carried out, including charging off these inactive items from the previous ECDL and charge-in appropriately in the updated ECDL, as mentioned in Appx “B’.
6. All ECHS Polyclinics are required to maintain comprehensive monthly record of medicine demands, particularly for newly included items, to support efficient procurement from the respective SEMOs.
7. Medicines which are not listed in the revised ECDL-2025 may be considered for inclusion on a case-to-case basis, only after obtaining recommendation from the respective SEMO.
8. Medicines prescribed by specialists of Service/Government/Empanelled hospitals that are not listed in revised ECDL-2025 shall follow reimbursement sanction as per CO ECHS letter reference mentioned at Para 1.2 above.
9, In view of the above, the copy of revised ECDL-2025 is forwarded herewith. All Regional Centres are requested to circulate this letter to all ECHS Polyclinics under their AoR and ensure strict compliance.
(Vikas Yadav)
Lt Col
Jt Dir (Med & Eqpt)
for MD ECHS
COMMENTS